Titre Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Protocole ID EMERGE 402 (JZP712-402)
ClinicalTrials.gov ID NCT04894591
Type(s) de cancer Poumon à petites cellules
Phase Phase IV
Stade Maladie avancée ou métastatique
Type étude Autre
Médicament Zepzelca
      143 rue Wolfe, Lévis, QC, G6V 3Z1
Ville Beauceville
Investigateur(trice) principal(e) Dre Danièle Marceau
Coordonnateur(trice) Pierre Bédard
Statut Actif en recrutement
Critètes d'éligibilité
  • Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.
  • Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
  • Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
Critètes d'exclusion
  • Patients who discontinued a prior Zepzelca treatment due to adverse events.
  • Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.
  • Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.